Larrousse M - Search Results

1

Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor.

Blanco JL, Biglia MA, Arnedo M, Martínez E, Mallolas J, Milinkovic A, Laguno M, Larrousse M, Leon A, Lonca M, García F, Miró JM, Pumarola T, Gatell JM. Blanco JL, et al. Among authors: larrousse m. AIDS. 2005 May 20;19(8):829-31. doi: 10.1097/01.aids.0000168978.89961.22. AIDS. 2005. PMID: 15867498

2

Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.

Martínez E, Larrousse M, Podzamczer D, Pérez I, Gutiérrez F, Loncá M, Barragán P, Deulofeu R, Casamitjana R, Mallolas J, Pich J, Gatell JM; BICOMBO Study Team. Martínez E, et al. Among authors: larrousse m. AIDS. 2010 Jan 28;24(3):F1-9. doi: 10.1097/QAD.0b013e32833562c5. AIDS. 2010. PMID: 20009917 Clinical Trial.

3

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.

Martínez E, Larrousse M, Llibre JM, Gutiérrez F, Saumoy M, Antela A, Knobel H, Murillas J, Berenguer J, Pich J, Pérez I, Gatell JM; SPIRAL Study Group. Martínez E, et al. Among authors: larrousse m. AIDS. 2010 Jul 17;24(11):1697-707. doi: 10.1097/QAD.0b013e32833a608a. AIDS. 2010. PMID: 20467288 Clinical Trial.

4

Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy.

Curran A, Martinez E, Saumoy M, del Rio L, Crespo M, Larrousse M, Podzamczer D, Burgos J, Lonca M, Domingo P, Gatell JM, Ribera E. Curran A, et al. Among authors: larrousse m. AIDS. 2012 Feb 20;26(4):475-81. doi: 10.1097/QAD.0b013e32834f3507. AIDS. 2012. PMID: 22112606 Clinical Trial.

5

Pancreatic toxic effects associated with co-administration of didanosine and tenofovir in HIV-infected adults.

Martínez E, Milinkovic A, de Lazzari E, Ravasi G, Blanco JL, Larrousse M, Mallolas J, García F, Miró JM, Gatell JM. Martínez E, et al. Among authors: larrousse m. Lancet. 2004 Jul 3-9;364(9428):65-7. doi: 10.1016/S0140-6736(04)16591-4. Lancet. 2004. PMID: 15234858

6

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.

Laguno M, Murillas J, Blanco JL, Martínez E, Miquel R, Sánchez-Tapias JM, Bargallo X, García-Criado A, de Lazzari E, Larrousse M, León A, Loncá M, Milinkovic A, Gatell JM, Mallolas J. Laguno M, et al. Among authors: larrousse m. AIDS. 2004 Sep 3;18(13):F27-36. doi: 10.1097/00002030-200409030-00003. AIDS. 2004. PMID: 15316335 Clinical Trial.

7

High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir.

León A, Mallolas J, Martinez E, De Lazzari E, Pumarola T, Larrousse M, Milincovic A, Lonca M, Blanco JL, Laguno M, Biglia A, Gatell JM. León A, et al. Among authors: larrousse m. AIDS. 2005 Oct 14;19(15):1695-7. doi: 10.1097/01.aids.0000186821.30489.16. AIDS. 2005. PMID: 16184042

8

Increased risk of pre-eclampsia and fetal death in HIV-infected pregnant women receiving highly active antiretroviral therapy.

Suy A, Martínez E, Coll O, Lonca M, Palacio M, de Lazzari E, Larrousse M, Milinkovic A, Hernández S, Blanco JL, Mallolas J, León A, Vanrell JA, Gatell JM. Suy A, et al. Among authors: larrousse m. AIDS. 2006 Jan 2;20(1):59-66. doi: 10.1097/01.aids.0000198090.70325.bd. AIDS. 2006. PMID: 16327320

9

Antiretroviral activity of didanosine in patients with different clusters of reverse transcriptase mutations.

Blanco JL, Biglia A, De Lazzari E, Mallolas J, Martinez E, Pumarola T, Larrousse M, Milinkovic A, León A, Lonca M, Laguno M, Gatell JM. Blanco JL, et al. Among authors: larrousse m. AIDS. 2006 Sep 11;20(14):1891-2. doi: 10.1097/01.aids.0000244210.33876.26. AIDS. 2006. PMID: 16954732

10

Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients.

Laguno M, Milinkovic A, de Lazzari E, Murillas J, Martínez E, Blanco JL, Loncá M, Biglia A, Leon A, García M, Larrousse M, García F, Miró JM, Gatell JM, Mallolas J. Laguno M, et al. Among authors: larrousse m. Antivir Ther. 2005;10(3):423-9. Antivir Ther. 2005. PMID: 15918333

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

73 results

Search Page

Filters